Adagene Inc.
NASDAQ:ADAGBiotechnology
+$0.13 today
- Market cap
- $55.72M
- Beta
- 0.59
- P/E (TTM)
- -7.9
- EPS (TTM)
- -$0.47
Volume 2.34M
Average 0.21M
ADAG EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Adagene Inc.NASDAQ: ADAG
EBITDA · Q4 FY2025 · quarter ended Dec 2025
EBITDA remains negative
Q4 FY2025 EBITDA was -$5.48M, compared with -$22.7M a year earlier. Trailing-twelve-month EBITDA was -$36.06M.
Context
- EBITDA amounted to 219.7% of revenue in FY2025, down 30460.8 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of -$20.65M (-22.5%) for the fiscal year ending Dec 2026, a slowdown from the +46.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$5.48M— QoQ
- Last fiscal yearDec 2025
- -$16.85M+46.8% YoY
- LTMJun 2024
- -$36.06M+9.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +75.8% | — | — |
| 1 year | +46.8% | -22.5% | -69.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (16.85M) USD
- Year-over-year change
- +46.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (16.85M) | +46.8% |
| FY2024 | 2024-12-31 | (31.66M) | -111.8% |
| FY2023 | 2023-12-31 | (14.95M) | +80.7% |
| FY2022 | 2022-12-31 | (77.39M) | -10.6% |
| FY2021 | 2021-12-31 | (69.99M) | — |
EBITDA vs competitors
How ADAG compares with its peers on the latest reported figures
- ADAG's LTM Jun 2024 EBITDA of -$36.06M is the 6th highest of the 9 companies compared; the peer median is -$29.02M.
- EBITDA amounts to 4420.7% of revenue for ADAG, versus a peer median of 727.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $148.02M | +264.5% | — | 223.7% | |
| LTM Apr 2026 | -$7.89M | +18.5% | — | 437.7% | |
| LTM Mar 2026 | -$20.2M | +0.1% | — | — | |
| LTM Mar 2026 | -$23.33M | -0.3% | — | 1017.5% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | -$34.71M | -256.5% | — | — |
| LTM Jun 2024 | -$36.06M | — | — | 4420.7% | |
| LTM Mar 2026 | -$38.33M | -3.1% | — | — | |
| LTM Mar 2026 | -$102.73M | +7.3% | — | — | |
| LTM Mar 2026 | -$118.65M | +4.8% | — | 1298.7% | |
| Peer median (excluding ADAG) | -$29.02M | +2.4% | — | 727.6% | |
Competitors are the stored peer set for ADAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.18M | 9.29M | 18.11M | 103.2K | 7.67M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 10.18M | 9.29M | 18.11M | (823.04K) | 7.67M |
| Gross Margin | 100.0% | 100.0% | 100.0% | -797.5% | 100.0% |
| Research & Development | 68.1M | 81.34M | 36.64M | 28.78M | 22.03M |
| Selling, General & Admin | 14.44M | 11.87M | 8.67M | 7.27M | 7.08M |
| Operating Expenses | 82.54M | 93.21M | 41.83M | 36.05M | 29.11M |
| Depreciation & Amortization | 1.13M | 1.43M | 1.21M | 926.25K | 589.79K |
| EBITDA | (69.99M) | (77.39M) | (14.95M) | (31.66M) | (16.85M) |
| EBITDA Margin | -687.8% | -832.8% | -82.5% | -30680.5% | -219.7% |
| Operating Income | (72.36M) | (83.92M) | (23.72M) | (35.95M) | (21.44M) |
| Operating Margin | -711.2% | -903.1% | -131.0% | -34835.4% | -279.5% |
| Interest Income | 76.17K | 377.5K | 4.28M | 3.8M | 2.3M |
| Interest Expense | 363.76K | 693.32K | 1.11M | 851.87K | 463.13K |
| Other Income / Expenses | 887.77K | 4.41M | 6.46M | 2.51M | 3.53M |
| Income Before Tax | (71.48M) | (79.51M) | (17.25M) | (33.44M) | (17.91M) |
| Pre-Tax Margin | -702.5% | -855.6% | -95.3% | -32403.5% | -233.4% |
| Income Tax Expense | 1.7M | 459.06K | 1.69M | (17.55K) | (297.86K) |
| Net Income | (73.18M) | (79.97M) | (18.95M) | (33.42M) | (17.61M) |
| Net Margin | -719.2% | -860.6% | -104.6% | -32386.4% | -229.6% |
| EPS (Basic) | (2.29) | (2.31) | (0.55) | (0.95) | (0.46) |
| EPS (Diluted) | (2.29) | (2.31) | (0.54) | (0.95) | (0.46) |
| Weighted Avg Shares | 32.02M | 34.65M | 34.64M | 36.02M | 37.76M |
| Weighted Avg Shares (Diluted) | 32.02M | 34.65M | 35.03M | 36.02M | 37.76M |
Adagene Inc.
NASDAQ:ADAG
Intrinsic Alpha fair value
Locked
Current Price
$1.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.